Medspa semaglutide costs range from $200–$600+ per month depending on dose, formulation source, and markup strategy—here's how the margin model works and what drives patient pricing.
Semaglutide pricing at medspas varies widely because the source matters: branded Ozempic or Wegovy carry manufacturer list prices, while compounded versions offer lower acquisition costs but carry regulatory and liability nuance. Most medspas offering semaglutide use compounded formulations, which wholesale for $100–$300 per month depending on dose and compounding pharmacy, then mark up 100–200% to retail prices of $200–$600 per month. Branded Wegovy (the GLP-1 indicated for weight loss) retails around $1,300–$1,500 per month at pharmacy, but few medspas stock it; those that do typically charge $1,200–$1,400 to remain competitive or absorb some margin to justify the premium positioning.
Compounded Semaglutide: The Medspa Standard
Compounded semaglutide dominates the medspa channel because it's cheaper to acquire and allows practices to set their own pricing. A compounding pharmacy typically charges a medspa $100–$250 per month for a standard 0.5–1.0 mg dose, depending on volume discounts, the pharmacy's sourcing, and whether the medspa has a standing relationship. The medspa then retails this at $250–$500 per month—a 100–150% margin is common for weight-loss wellness services, similar to IV therapy and vitamin infusions.
The regulatory reality: compounded semaglutide is not FDA-approved as a finished product. It exists in a gray zone. The FDA has issued warning letters to compounding pharmacies for semaglutide, citing lack of FDA oversight of the compounded formulation's sterility, potency, and purity. However, compounding itself is legal under the Pharmacy Compounding Accreditation Board (PCAB) framework and state pharmacy boards, provided the compounder sources from a licensed pharmaceutical manufacturer (not from diverted Ozempic vials). A medspa offering compounded semaglutide assumes liability risk—if a patient has an adverse event, the lack of FDA approval and the compounding status complicate the liability picture. Insurance rarely covers compounded semaglutide; patients pay out-of-pocket.
Branded Wegovy: Higher Cost, Lower Medspa Adoption
Branded Wegovy (semaglutide 2.4 mg pre-filled pen, indicated for chronic weight management) costs roughly $1,300–$1,500 per month at retail pharmacy, though GLP-1 shortages and manufacturer allocation have created pricing volatility. A medspa that stocks Wegovy typically acquires it through a pharmaceutical wholesaler (Cardinal, McKesson, AmerisourceBergen) at a negotiated cost close to wholesale acquisition cost (WAC), which is lower than retail but still $800–$1,100 per unit depending on volume and rebate programs.
Few medspas carry Wegovy because the margin is thin: a medspa paying $900 for a pen and retailing it at $1,200–$1,300 nets only $300–$400 per unit, versus $150–$250 per unit on a compounded vial. Additionally, Wegovy requires a prescription from a licensed provider (MD, DO, NP, PA), and the medspa must have prescribing authority or a supervising physician on staff—adding compliance overhead. Branded Wegovy also carries FDA approval, which reduces liability exposure compared to compounded formulations.
Dose, Frequency, and Total Patient Cost
Compounded semaglutide wholesales at $100–$250/month and retails at $250–$500, yielding 100–150% margins; branded Wegovy costs $800–$1,100 to acquire but retails at only $1,200–$1,300, making it a lower-margin play.
Semaglutide dosing for weight loss typically starts at 0.25 mg weekly and escalates to 1.0 mg or 2.4 mg over 4–16 weeks. A patient on a standard 1.0 mg weekly protocol at a medspa charging $300/month pays $3,600 annually. If the medspa offers a package (e.g., 12 weeks for $800), the per-injection cost drops but locks in revenue upfront.
Medspas often bundle semaglutide with nutrition counseling, lifestyle coaching, or monthly labs (metabolic panel, lipids) to justify premium pricing and differentiate from telehealth GLP-1 prescribers (who charge $100–$300/month for the script alone, leaving patients to fill at pharmacy). This bundled model can command $400–$600/month and improves patient retention and lifetime value.
Key Margin Drivers
- Acquisition source: compounded ($100–$250/month) vs. branded ($800–$1,100/unit)
- Dose and volume discounts: higher-dose compounded formulations or bulk orders reduce per-unit cost
- Markup strategy: weight-loss wellness typically 100–200% margin; branded Wegovy 30–50% margin
- Bundling: adding coaching, labs, or follow-up visits justifies higher retail pricing
- Liability and compliance: branded carries lower risk; compounded requires clear informed consent and documentation
- Patient population: cash-pay aesthetic clients tolerate higher pricing; medical-weight-loss referrals may be price-sensitive
Regulatory and Compliance Considerations
If offering compounded semaglutide, verify that your compounding pharmacy holds PCAB accreditation and sources from a licensed manufacturer. Document informed consent explicitly noting the compounded status and lack of FDA approval. Ensure prescribing authority (your own license or a supervising physician) and compliance with state scope-of-practice rules for nurse injectors or aestheticians administering the injections.
For branded Wegovy, confirm your wholesaler account and rebate eligibility (some manufacturers offer volume rebates that lower effective cost). Verify insurance coverage policies with major plans in your region—coverage is improving but remains inconsistent.
The margin model works because semaglutide is a high-perceived-value service in the aesthetic and wellness space. Patients seeking weight loss at a medspa are often willing to pay a premium for convenience, personalization, and the integrated aesthetic/wellness experience—making semaglutide a strong revenue driver if priced and positioned correctly.
Frequently asked questions
How much does semaglutide cost at a medspa per month?
Medspa semaglutide pricing ranges from $200–$600+ per month depending on dose and formulation source. Compounded semaglutide typically costs $250–$500 monthly, while branded Wegovy runs $1,200–$1,400 per month at medspas that stock it. Most medspas use compounded formulations because they allow higher margins and lower acquisition costs.
What's the difference between compounded and branded semaglutide at medspas?
Compounded semaglutide is mixed by a pharmacy and costs medspas $100–$250 to acquire, then retails for $250–$500 (100–150% markup). Branded Wegovy is FDA-approved, costs medspas $800–$1,100 to acquire, and retails for $1,200–$1,400 with thinner margins. Compounded semaglutide carries regulatory gray-zone status and liability risk; Wegovy has FDA approval but fewer medspas stock it due to lower profit per unit.
Is compounded semaglutide FDA-approved?
No—compounded semaglutide is not FDA-approved as a finished product and exists in a regulatory gray zone. The FDA has issued warning letters to compounding pharmacies over sterility, potency, and purity concerns. Compounding is legal under PCAB and state pharmacy board oversight if sourced from a licensed pharmaceutical manufacturer, but medspas offering it assume liability risk if adverse events occur.
How much does a medspa markup semaglutide?
Medspas typically mark up compounded semaglutide 100–150%, acquiring it for $100–$250 per month and retailing it at $250–$500. Branded Wegovy carries a thinner 30–50% markup because medspas pay $800–$1,100 wholesale and retail at $1,200–$1,400, netting only $300–$400 profit per unit versus $150–$250 on compounded formulations.
What does semaglutide cost per year at a medspa?
A patient on a standard 1.0 mg weekly protocol at a medspa charging $300/month pays approximately $3,600 annually. Medspas sometimes offer package deals (e.g., 12 weeks for $800) that lower per-injection cost but lock in revenue upfront. Total annual cost depends on dose escalation and whether the patient continues beyond the initial weight-loss phase.
Why do most medspas use compounded semaglutide instead of Wegovy?
Medspas prefer compounded semaglutide because acquisition costs are lower ($100–$250 vs. $800–$1,100 for Wegovy) and margins are higher (100–150% vs. 30–50%). Branded Wegovy also requires prescribing authority or a supervising physician on staff, adding compliance overhead. The thinner profit per unit makes Wegovy less attractive for most medspa business models.
Free weekly brief Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
